In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
in_silico_and_preclinical_2017.pdf
(Tampereen yliopisto - Trepo)
Tallennettuna:
Kieli |
englanti |
---|---|
ISSN |
2044-5385 |